Peptide Schedule
Lixisenatide44 residuesHGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSKKKKKKEach bubble = one amino acid. Size = residue mass. Color = chemical class.Lixisenatide Dosage Calculator
Lixisenatide is a 44-amino-acid synthetic peptide derived from exendin-4, a compound originally isolated from the saliva of the Gila monster (Heloderma suspectum).
10mcg · Daily
Summary: Add 0mL BAC water to your 10mg vial. Draw to < 0.1 units on a U-100 syringe for a 10mcg dose. This vial will last 0 doses.
Cycle Planner
Lixisenatide Pharmacokinetics
Pharmacokinetics — Active Dose Over Time
t½ = ~3 hoursDisclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
Lixisenatide Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 10mcg | Daily |
| Moderate | 20mcg | Daily |
| Aggressive | 20mcg | Daily |
Note: Lixisenatide (brand names: Adlyxin in the US, Lyxumia in the EU) is an FDA-approved short-acting GLP-1 receptor agonist for type 2 diabetes. It is a pre-filled pen — no reconstitution needed. Start at 10 mcg SC once daily for 14 days, then increase to 20 mcg once daily. Inject within one hour before the first meal of the day. Also available as Soliqua 100/33 (fixed-ratio combination with insulin glargine). Note: Adlyxin was discontinued in the US market as of January 1, 2023, though Soliqua remains available.
About Lixisenatide
Lixisenatide is a 44-amino-acid synthetic peptide derived from exendin-4, a compound originally isolated from the saliva of the Gila monster (Heloderma suspectum). Like exenatide, it is built on the exendin-4 backbone but with key structural modifications: deletion of a proline at position 38 and addition of six lysine residues at the C-terminus. These changes give it a four-fold higher binding affinity for the GLP-1 receptor compared to native human GLP-1. Sanofi developed lixisenatide and received EU marketing authorization (as Lyxumia) in 2013, followed by FDA approval (as Adlyxin) in July 2016. It was classified as a short-acting GLP-1 receptor agonist based on its approximately 3-hour half-life, which distinguishes it from long-acting agents like semaglutide and dulaglutide. This short duration of action gives it a particularly strong effect on postprandial glucose — especially after the meal closest to injection — rather than round-the-clock GLP-1 receptor activation. The GetGoal clinical trial program (11 Phase III trials) established its efficacy across the type 2 diabetes spectrum. As monotherapy or add-on to oral agents or basal insulin, lixisenatide consistently reduced HbA1c by 0.5-1.0% and produced modest weight loss of 0.4-2.7 kg. The ELIXA cardiovascular outcomes trial (6,068 patients with recent acute coronary syndrome) confirmed cardiovascular safety — it neither increased nor decreased major cardiac events (HR 1.02, 95% CI 0.89-1.17). In 2017, the FDA approved Soliqua 100/33, a fixed-ratio combination of insulin glargine and lixisenatide in a single pen. This combination targets both fasting glucose (via basal insulin) and postprandial spikes (via lixisenatide) and showed superior HbA1c reduction compared to either component alone in the LixiLan trial program. While standalone Adlyxin was discontinued in the US in January 2023, Soliqua remains commercially available.